Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Arbutus Biopharma Corp is a biotechnology business based in the US. Arbutus Biopharma shares (ABUS) are listed on the NASDAQ and all prices are listed in US Dollars. Arbutus Biopharma employs 85 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.80 |
|---|---|
| 52-week range | $1.93 - $6.50 |
| 50-day moving average | $2.49 |
| 200-day moving average | $3.25 |
| Wall St. target price | $6.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.71 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.8 from 2022-07-01
| 1 week (2022-06-28) | 7.28% |
|---|---|
| 1 month (2022-06-01) | N/A |
| 3 months (2022-04-05) | -8.79% |
| 6 months (2022-01-03) | -29.65% |
| 1 year (2021-07-02) | -5.08% |
|---|---|
| 2 years (2020-07-02) | 48.94% |
| 3 years (2019-07-05) | 24.44% |
| 5 years (2017-07-05) | 3.75 |
| Revenue TTM | $21.5 million |
|---|---|
| Gross profit TTM | $-54,514,000 |
| Return on assets TTM | -21.82% |
| Return on equity TTM | -54.02% |
| Profit margin | 0% |
| Book value | $1.12 |
| Market capitalisation | $403.1 million |
TTM: trailing 12 months
We're not expecting Arbutus Biopharma to pay a dividend over the next 12 months.
Arbutus Biopharma's shares were split on a 1:5 basis on 3 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma shares which in turn could have impacted Arbutus Biopharma's share price.
Over the last 12 months, Arbutus Biopharma's shares have ranged in value from as little as $1.93 up to $6.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma's is 2.6588. This would suggest that Arbutus Biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc. ; Gritstone Oncology, Inc. ; Alnylam Pharmaceuticals, Inc. ; Qilu Pharmaceuticals Co, Ltd.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.